# JAVELIN Medley (NCT02554812)

> A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

No report yet. It can be ordered.

- Drugs tested: avelumab plus utomilumab; avelumab plus ivuxolimab (PF-04518600); avelumab plus PD 0360324
- Indication: advanced malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02554812
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Pfizer
- Conditions: Advanced Cancer
- Interventions: Avelumab; Utomilumab; PF-04518600; PD 0360324; CMP-001
- Enrollment: 409
- Primary outcome: Phase 1b Lead-in: Number of Participants With First 2 Cycles Dose Limiting Toxicity (DLT) for Combination A
- Primary outcome: Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination B
- Primary outcome: Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination C
- Primary outcome: Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination D
- Primary outcome: Phase 1b Lead-in: Number of Participants With First Cycle DLT for Combination F
- Primary outcome: Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment for Combination A
- Primary outcome: Phase 2: Percentage of Participants With Confirmed OR as Per RECIST v 1.1 by Investigator Assessment for Combination B

## Questions raised in the commentary

_Automated from all 15 indexed sources (Jan 2024 – Aug 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether the combination improves overall survival
- How toxicity affects use in the maintenance setting
- Which patients may benefit, and whether biomarkers can identify them
- How the combination fits alongside current first-line therapy

Also discussed: Trop-2 targeting.

## Indexed commentary on JAVELIN Medley so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- Podcasts: 6
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=javelin-medley-nct02554812

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02554812", "email": "<work email>"}; the inbox owner confirms by the emailed link.